Research Article
Formulation Development and Stability Studies of Norfloxacin Extended-Release Matrix Tablets
Table 2
Pharmacopeial characteristics of norfloxacin matrix tablets.
| | Formulation | Weight (g)a | Hardness (KgF)b | Water loss (%) | Friability (%)a | | Uncoated | Coated | Uncoated | Coated | Uncoated | Coated | Uncoated |
| | HPMC K100LV 20% | 1.1154 | 1.1472 | 16.3 | 17.0 | 7.75 | 7.29 | 0.021 | | HPMC K100LV 30% | 1.1025 | 1.1321 | 14.8 | 16.4 | 7.93 | 7.60 | 0.014 | | HPMC K4M 20% | 1.1033 | 1.1314 | 13.1 | 15.1 | 7.08 | 6.60 | 0.034 | | HPMC K4M 30% | 1.0795 | 1.1119 | 13.0 | 14.5 | 7.29 | 7.11 | 0.018 | | PEO N60K 20% | 1.0858 | 1.1193 | 14.2 | 15.7 | 7.02 | 5.08 | 0.017 | | PEO N60K 30% | 1.0854 | 1.1131 | 16.9 | 17.7 | 6.77 | 5.64 | 0.021 | | PEO 301 20% | 1.0831 | 1.1162 | 16.6 | 18.8 | 7.16 | 6.91 | 0.018 | | PEO 301 30% | 1.1014 | 1.1306 | 16.0 | 17.5 | 7.09 | 7.01 | 0.023 |
|
|
Mean of twenty determinations; bmean of ten determinations.
|
